A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors
Interventions: DRUG: ASP1948|DRUG: nivolumab|DRUG: pembrolizumab
Sponsor: Astellas Pharma Global Development, Inc.
Collaborators: Merck Sharp & Dohme LLC